Sponsored Early-Career Research Grant
The Sponsored Early-Career Research Grant (ECR), supported by Acerta Pharma, a member of the AstraZeneca Group, will provide funding to promising investigators early in their career to encourage and promote quality, basic, and pre-clinical translational lab-based research, although clinical research may also be considered, in hematology/oncology among HOPA members. The purpose of this award is to fund US-based pharmacists within their first 7 years post completion of formal training and have not yet attained R21 level funding. The Acerta Pharma supported ECR Grant will award up to $50,000 to the chosen applicant, paid in two equal installments over a two-year period.
The grant funds will be used to provide an ECR award to individuals whose research has an emphasis on hematology research, primarily within research concerning Chronic Lymphocytic Leukemia (CLL), B‐Cell Malignancies, and Non‐Hodgkin’s lymphomas.
The sponsored ECR Grant will award $50,000 to the chosen applicant, paid in two equal installments over a two-year period.
Learn more about the Sponsored Early-Career Research Grant.
Research Fund Award
The Research Fund Award is intended to support a hematology/oncology pharmacy practice research project with subsequent publication that aligns closely with the HOPA strategic plan to demonstrate the value of hematology/ oncology pharmacy practice. Pharmacy practice is broadly defined to include areas of research such as: clinical or patient outcomes, surveys, patient safety, standards validation, and basic/translational science applications. Multiple institutions may be involved in the project, and a project with co-PIs are allowed. A subsequent publication resulting from the research project is expected within a year of the study completion.
A total of $100,000 is available to be awarded to up to three grants through a competitive peer-review process described below. HOPA aims to fund at least one practice-based and one basic/translational study.
Learn more about the Research Fund Award. Call for LOIs is now open. Deadline to apply is Monday, July 27, at 11:59 pm Central.
Early-Career Research Grant
The HOPA Early-Career Research Grant (ECR) will provide funding to promising investigators early in their career to encourage and promote quality basic and pre-clinical translational lab-based research in oncology among HOPA members. The purpose of this award is to fund United States based pharmacists within the first 7 years post completion of formal training who have not yet attained R21 level funding. Mentoring will be an essential component of the ECR Grant. Awarded early career pharmacists will be required to work with a mentor either from their sponsoring institution or to find a mentor from another institution within the United States.
The HOPA ECR Grant will award $50,000 to the chosen applicant, paid in two equal installments over a two-year period.
Learn more about the Early-Career Research Grant. Call for LOIs is now open. Deadline to apply is Monday, July 27, at 11:59 pm Central.
HOPA Sponsorship of ACCP FIT/MeRIT Program
Previously, in an effort to help provide more research training and resources to our members, HOPA has sponsored grant awardees the opportunity to participate in the ACCP FIT/MeRIT program to strengthen the success of the HOPA sponsored research. Recent discussions in the HOPA Basic Science and Translational Research Committee identified this would be an excellent opportunity for HOPA members that are interested but not well prepared to submit grant applications to attend and participate in the ACCP FIT or MeRIT program to build a strong foundation and will ultimately strengthen the quality of oncology pharmacy research. HOPA is pleased to share that we will be sponsoring tuition for up to five qualified members to the ACCP FIT or MeRIT Program. Program details are linked here. All questions and submission should be directed to Hannah Lipton.
To learn more about the program, please follow the below links. Deadlines for the full applications to HOPA are Wednesday, March 31st 2021 at Midnight.